TY - JOUR
T1 - Decreased levels of [Met]enkephalin, neuropeptide Y, substance P, and vasoactive intestinal peptide in parkinsonian adrenal medulla
AU - Stoddard, Susan L.
AU - Tyce, Gertrude M.
AU - Ahlskog, J. Eric
AU - Zinsmeister, Alan R.
AU - Nelson, Daniel K.
AU - Carmichael, Stephen W.
N1 - Funding Information:
The authors appreciate the comments of Dr. F. Javoy-Agid on this manuscript and thank Dr. H. Okazaki for neuropathological examination, Sharon Chinnow for performing the catecholamine assays, and the following people for performing the peptide assays: Diane R. Roddy (NPY and BLI), Jane E. Bailey (SP), Mary Jo Wertzler (VIP), Darlene L. Lucas ([Met]ENK), and Barbara L. Furlow (PYY). This work was supported, in part, by grants from the United Parkinson Disease Foundation (S.W.C.), by NS 17858 (G.M.T.), and by NIH DK34988 (Digestive Diseases Core Center).
PY - 1991/10
Y1 - 1991/10
N2 - Adrenal medullary tissue was collected from parkinsonian patients at autopsy and at the time of autologous transplantation of the adrenal medulla to the caudate nucleus, and from nonparkinsonian patients at autopsy and during nephrectomy. Levels of the following neuropeptides were measured by radioimmunoassay in samples of the medullary tissue: neuropeptide Y (NPY), substance P (SP), [Met]enkephalin ([Met]ENK), vasoactive intestinal peptide (VIP), peptide YY, and bombesin-like immunoreactivity. Regression analysis was used to establish a relationship between patient age, time to organ harvest, and peptide levels in nonparkinsonian tissue. Levels of [Met]ENK, VIP, NPY, and SP were significantly lower in parkinsonian adrenal medullae than that predicted from the control group. These results suggest that the adrenal medulla of a parkinsonian patient is severely compromised, either by the disease process itself or by the antiparkinsonian medications used to treat the symptoms of the disease.
AB - Adrenal medullary tissue was collected from parkinsonian patients at autopsy and at the time of autologous transplantation of the adrenal medulla to the caudate nucleus, and from nonparkinsonian patients at autopsy and during nephrectomy. Levels of the following neuropeptides were measured by radioimmunoassay in samples of the medullary tissue: neuropeptide Y (NPY), substance P (SP), [Met]enkephalin ([Met]ENK), vasoactive intestinal peptide (VIP), peptide YY, and bombesin-like immunoreactivity. Regression analysis was used to establish a relationship between patient age, time to organ harvest, and peptide levels in nonparkinsonian tissue. Levels of [Met]ENK, VIP, NPY, and SP were significantly lower in parkinsonian adrenal medullae than that predicted from the control group. These results suggest that the adrenal medulla of a parkinsonian patient is severely compromised, either by the disease process itself or by the antiparkinsonian medications used to treat the symptoms of the disease.
UR - http://www.scopus.com/inward/record.url?scp=0026044773&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026044773&partnerID=8YFLogxK
U2 - 10.1016/0014-4886(91)90080-V
DO - 10.1016/0014-4886(91)90080-V
M3 - Article
C2 - 1915731
AN - SCOPUS:0026044773
SN - 0014-4886
VL - 114
SP - 23
EP - 27
JO - Experimental Neurology
JF - Experimental Neurology
IS - 1
ER -